Upon entering the biological milieu, nanomedicines swiftly interact with the surrounding
tissue fluid, subsequently being enveloped by a dynamic interplay of biomacromolecules …

Proteolysis-targeting chimeras (PROTACs) have been an area of intensive research with the
potential to extend drug space not target to traditional molecules. In the last half decade, we …

Cuproptosis is a novel copper‐dependent programmed cell death. The efficacy of
cuproptosis is highly dependent on intracellular copper accumulation and counteracted by a …

Tumor‐associated macrophages (TAMs) play a critical role in the immunosuppressive solid
tumor microenvironment (TME), yet in situ engineering of TAMs for enhanced tumor …

Immunotherapy as an alternative treatment strategy for B-cell lymphoma is undesirable
because of tumor heterogeneity and immune surveillance. Spermidine (SPM), as a regulator …

Drug development remains a critical focus within the global pharmaceutical industry. To
date, more than 80% of disease targets are considered difficult to target. The emergence of …

The invention of silica-based bioactive glass in the late 1960s has sparked significant
interest in exploring a wide range of silicon-containing biomaterials from the macroscale to …

The development of non-interventional combination therapy with immune activation property
provides a potential direction for solving the diversity, complexity and heterogeneity of …

Targeted protein degradation (TPD) has emerged as a revolutionary paradigm in drug
discovery and development, offering a promising avenue to tackle challenging therapeutic …

Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention
over the last 10 years, representing a burgeoning therapeutic approach with the potential to …